Regional variation in breast cancer treatment in the Netherlands and the role of external peer review: a cohort study comprising 63,516 women

Melvin J Kilsdonk1,2*, Boukje AC van Dijk1,3, Renee Otter1, Wim H van Harten2,4 and Sabine Siesling1,2

Abstract

Background: Treatment variation is an important issue in health care provision. An external peer review programme for multidisciplinary cancer care was introduced in 1994 in the Netherlands to improve the multidisciplinary organisation of cancer care in hospitals. So far the clinical impact of external quality assessment programmes such as external peer review and accreditation remains unclear. Our objective was to examine the degree of variation in treatment patterns and the possible effect of external peer review for multidisciplinary cancer care for breast cancer patients.

Methods: Patients with breast cancer were included from 23 hospitals from two ‘intervention regions’ with the longest experience with the programme and 7 hospitals that never participated (control group). Data on tumour and treatment characteristics were retrieved from the Netherlands Cancer Registry. Treatment modalities investigated were: the completeness of breast conserving therapy, introduction of the sentinel node biopsy, radiotherapy after breast conserving surgery for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Hospitals from the two intervention regions were dichotomised based on their implementation proportion (IP) of recommendations from the final reports of each peer review (high IP vs. low IP). This was regarded as a measure of how well a hospital participated in the programme.

Results: 63,516 female breast cancer patients were included (1990-2010). Variation in treatment patterns was observed between the intervention regions and control group. Multidisciplinary treatment patterns were not consistently better for patients from hospitals with a high IP.

Conclusions: There is no relationship between the external peer review programme for multidisciplinary cancer care and multidisciplinary treatment patterns for breast cancer patients. Regional factors seem to exert a stronger effect on treatment patterns than hospital participation in external peer review.

Keywords: Breast neoplasms, Cohort studies, Healthcare quality assessment, Quality improvement, Peer review

Background

Breast cancer is the commonest cancer in women in the Netherlands and its burden increased during the last decades due to a steady rise in incidence [1]. Survival rates have improved because of better imaging and detection techniques, screening programmes and the introduction of new therapies [2,3]. Breast cancer treatment is marked by a multidisciplinary approach and specialisation of the involved medical and nursing specialists. A recent study in 13,722 women showed that improving multidisciplinary care was associated with improved survival and reduced variation in survival among hospitals [4]. Specialisation of physicians is an important component of multidisciplinary care and is associated with better outcomes for various cancers [5]. A study in the UK revealed an 11-17% reduction in risk of death in women treated for breast cancer.
as a result of specialisation of surgeons [6]. Similar results were seen in other types of cancer and during the 90's multidisciplinary care became the standard of cancer care. It is known that treatment variation exists between and within countries and it is unknown whether and how these differences interact with improvement efforts. This poses serious challenges in efforts to evaluate quality improvement programmes.

Several quality improvement methods are used to improve the multidisciplinary organisation of care and reduction of variation. In the Netherlands an external peer review programme was introduced in 1994. Designed and executed by medical and nursing cancer specialists, it was introduced in the Northern Netherlands and gradually spread over the entire country. The programme focuses on the organisational conditions to provide optimal cancer care. Participation is voluntary and hospitals are advised to participate in cycles of 4–5 years. After a self-assessment, on-site observation and interviews, the organisation of cancer care in a hospital is evaluated and recommendations for improvement are given. Major topics of recommendations were the organisation of weekly multidisciplinary patient care meetings, shared decision making between specialists, oncological specialisation of medical specialists, dedication of oncology committees (with representatives of all medical specialisms) to policy making, referral policies for rare tumours and highly complicated interventions, introduction of integrated care pathways and working to evidence based guidelines.

More information on the programme can be found in Additional file 1.

In general, the clinical impact of external peer review remains under-investigated. A study evaluating a peer review programme for chronic obstructive pulmonary disease in the United Kingdom found an association with improved quality of care, service delivery and changes that promote quality improvement after three years [7]. The evaluation after one year revealed no differences showing that changes in healthcare can take a prolonged period to occur [8]. Accreditation is the most frequently studied form of external quality assessment. Literature reviews on the effects of accreditation on the quality of care could not provide strong evidence due to limitations of the studies [9,10]. The programmes demand high financial and labour investments and therefore there is a need for more research on the clinical impact of these programmes [11,12].

The purpose of our study was to investigate the multidisciplinary treatment patterns of breast cancer patients and the effect of the external peer review programme for multidisciplinary cancer care in general hospitals. In a previous study we found some positive effects on colorectal cancer treatment, but the results needed to be interpreted cautiously due to the ambiguity of the outcomes and possible confounding factors [13]. In the current study we examined whether our previous results are also evident in breast cancer treatment. More importantly, by analysing different regions separately we hope to gain more insights in possible regional confounders. We hypothesised that the willingness of a hospital to have external peer review and to follow the recommendations from it, is correlated to the hospital giving higher quality of breast cancer treatment measured by the introduction of new multidisciplinary therapies.

**Methods**

**Design and patients**

Only female patients diagnosed with primary epithelial breast cancer (ICD-O 10, International Classification of Diseases, codes: C50.0 to 50.9) between 1 January 1990 and 31 December 2010 were selected from the Netherlands Cancer Registry (NCR). This is a population based independent cancer registry containing clinical administrative data of every newly diagnosed cancer patient in the Netherlands. Data is collected directly from the hospitals’ patient files by specially trained registration clerks. Topography and morphology is coded according to the International Classification of Diseases for Oncology (ICD-O) and staging according to the TNM-classification. Follow-up of vital status is achieved by linkage of the registry to municipal records. The quality of the data is high [14] and completeness is estimated to be at least 95% [15].

Patients were included from hospitals in the Northern Netherlands and the Rotterdam region. In these regions the external peer review programme was introduced first (intervention regions). Patients from hospitals from other regions that never participated before 2009 were included in the control group. We excluded patients that were diagnosed with neuroendocrine tumours, synchronous tumours, diagnosed at autopsy and that had any type of previous malignancy.

**Hospital categories**

Hospitals from the intervention group were categorised by the implementation proportion (IP) of recommendations that were given in the final reports of each peer review. We dichotomised the intervention region hospitals by their IP (high IP vs. low IP, no threshold was used). We regarded the IP of the recommendations as a proxy of how well a hospital participated in the programme. Rating the implementation was performed by studying final reports from subsequent reviews, follow-up correspondence, hospital documents and interviews with stakeholders when necessary. Implementation of a recommendation was ranked on a scale from 0 to 4 (Table 1). The IP per hospital was expressed as a percentage of the total possible score. When implementation of a recommendation could not be
determined (lost to follow-up), this recommendation was subtracted from the total possible score. The average IP of all peer reviews per hospital was used because it is not known what the time period is in which changes based on organisational change can occur and quality improvement is a continuous process. Ranking the implementation of recommendations was performed by the principal investigator. If e.g. the report from the next peer-review states that a recommendation was not implemented at all this was ranked as zero. Full implementation was ranked as 4, examples of recommendations and their ranking can be seen in Table 1. Due to the objective nature of the evidence the ranking was not considered to be arbitrarily and we did not use an inter-rater approach.

From the hospitals in the two intervention regions we used data from two or three cycles of participation:

- Northern Netherlands: three cycles, 1994–2009.
- Rotterdam region: two cycles, 1996–2006. A third cycle was completed between 2009 and 2011 but follow-up time was too short to monitor the IP.

All hospitals in these regions voluntarily participated in the peer review programme. The university medical centres and hospitals that merged during our study period were excluded, because it was impossible to follow-up the recommendations. Hospitals were asked to participate in the study by giving permission to use their data from the NCR and final reports.

### Analyses

We analysed the Northern Netherlands and Rotterdam region separately to gain more insights in possible regional confounders besides the external peer review programme. Patients were grouped according to the hospital in which the diagnosis was made. They may have been referred for treatment but this was regarded to be good clinical practice (and referral policy is a theme of the programme). Multivariate logistic analysis was used to analyse treatment variation and the influence of hospital category (based on IP), gender, age at diagnosis, year of diagnosis, average hospital volume of diagnoses and presence of an in-hospital radiotherapy department. We studied several multidisciplinary treatment modalities. First of all, we studied the completeness of breast conserving therapy (BCT). From its introduction onwards, breast conserving therapy is a multidisciplinary procedure and one of the earliest examples of multidisciplinary cancer treatment. Breast conserving surgery (BCS) was initially complemented with axillary lymph node dissection (ALND) and radiotherapy. Omission of lymph node dissection is allowed after a negative sentinel node biopsy (SNB). In our analyses, BCT was considered complete if radiotherapy had been given and ALND was performed or when radiotherapy is given, SNB was performed and ALND was omitted. We separately analysed the introduction of the sentinel node biopsy. Other indicators for treatment variation were taken from the indicator list defined by the NABON (National Breast Cancer Network Netherlands) in 2009. This list is part of a national audit on the quality of breast cancer diagnostics and treatment (NBCA) that started in 2011 [16]. These indicators are: radiotherapy after BCS for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Although the NBCA was established in 2011, data on the selected indicators were available since 1990. We could therefore look in retrospect at the period from 1990 onwards to evaluate how hospitals performed on these quality indicators that we now regard to be the standard of care for breast cancer patients.

For the analyses of completeness of breast conserving therapy and adjuvant chemotherapy for early stage breast cancer diagnostics and treatment (NBCA) that started in 2011 [16]. These indicators are: radiotherapy after BCS for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Although the NBCA was established in 2011, data on the selected indicators were available since 1990. We could therefore look in retrospect at the period from 1990 onwards to evaluate how hospitals performed on these quality indicators that we now regard to be the standard of care for breast cancer patients.

For the analyses of completeness of breast conserving therapy and adjuvant chemotherapy for early stage breast cancer diagnostics and treatment (NBCA) that started in 2011 [16]. These indicators are: radiotherapy after BCS for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Although the NBCA was established in 2011, data on the selected indicators were available since 1990. We could therefore look in retrospect at the period from 1990 onwards to evaluate how hospitals performed on these quality indicators that we now regard to be the standard of care for breast cancer patients.

For the analyses of completeness of breast conserving therapy and adjuvant chemotherapy for early stage breast cancer diagnostics and treatment (NBCA) that started in 2011 [16]. These indicators are: radiotherapy after BCS for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Although the NBCA was established in 2011, data on the selected indicators were available since 1990. We could therefore look in retrospect at the period from 1990 onwards to evaluate how hospitals performed on these quality indicators that we now regard to be the standard of care for breast cancer patients.

For the analyses of completeness of breast conserving therapy and adjuvant chemotherapy for early stage breast cancer diagnostics and treatment (NBCA) that started in 2011 [16]. These indicators are: radiotherapy after BCS for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Although the NBCA was established in 2011, data on the selected indicators were available since 1990. We could therefore look in retrospect at the period from 1990 onwards to evaluate how hospitals performed on these quality indicators that we now regard to be the standard of care for breast cancer patients.

For the analyses of completeness of breast conserving therapy and adjuvant chemotherapy for early stage breast cancer diagnostics and treatment (NBCA) that started in 2011 [16]. These indicators are: radiotherapy after BCS for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Although the NBCA was established in 2011, data on the selected indicators were available since 1990. We could therefore look in retrospect at the period from 1990 onwards to evaluate how hospitals performed on these quality indicators that we now regard to be the standard of care for breast cancer patients.

For the analyses of completeness of breast conserving therapy and adjuvant chemotherapy for early stage breast cancer diagnostics and treatment (NBCA) that started in 2011 [16]. These indicators are: radiotherapy after BCS for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Although the NBCA was established in 2011, data on the selected indicators were available since 1990. We could therefore look in retrospect at the period from 1990 onwards to evaluate how hospitals performed on these quality indicators that we now regard to be the standard of care for breast cancer patients.

For the analyses of completeness of breast conserving therapy and adjuvant chemotherapy for early stage breast cancer diagnostics and treatment (NBCA) that started in 2011 [16]. These indicators are: radiotherapy after BCS for ductal carcinoma in situ (DCIS), adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), adjuvant chemotherapy for early stage breast cancer (T1-2/N+/M0) and neo-adjuvant chemotherapy for T4/M0 breast cancer. Although the NBCA was established in 2011, data on the selected indicators were available since 1990. We could therefore look in retrospect at the period from 1990 onwards to evaluate how hospitals performed on these quality indicators that we now regard to be the standard of care for breast cancer patients.
cancer pathological stage was used and substituted with clinical stage if pathological stage was unknown. For the rest of the analyses clinical stage was used substituted by pathological stage if unknown. STATA version 12.0 was used for all analyses. Written syntaxes guarantee reproducibility of the results. P values were considered significant if smaller than 0.05.

Results

Hospitals and recommendations
Twenty-six hospitals from the Northern Netherlands and Rotterdam region were asked to give permission to use the data from their peer reviews and the Netherlands Cancer Registry. Twenty-three gave permission: 13 hospitals from the Northern Netherlands and 10 from the Rotterdam region. Seven out of twelve hospitals without experience with the programme agreed to be included in the control group. In total, our study includes patient data from 30 hospitals, approximately one-third of all hospitals in the Netherlands. In the three cycles of peer review in the Northern Netherlands and two cycles in the Rotterdam region 727 recommendations were given, averaging 12 recommendations per peer review per hospital. The intervention hospitals in both regions were dichotomised based on the IP of the recommendations. The Northern Netherlands region was divided in 6 hospitals with a high IP (average IP 63.2%) and 7 hospitals with a low IP (average IP 48.9%). The Rotterdam region was dichotomised in 5 hospitals with a high IP (average IP 63.2%) and 5 with a low IP (average 41.4%).

Patients
Our total cohort consists of 63,516 women. Table 2 shows the characteristics of the population grouped by their hospital category. There were no large differences in mean age at diagnosis and the number of patients per period of diagnosis between patients diagnosed in the different hospital categories. The average annual case volume differs between the regions, as in the Rotterdam region no hospitals with less than 50 patients diagnosed annually existed in the period under study. For only two hospital categories hospitals with more than 100 diagnosis per year existed (Northern Netherlands high IP and control group, Table 2).

Completeness of breast conserving therapy
Incomplete breast conserving therapy, omitting radiotherapy and/or ALND after breast conserving surgery rarely occurred (Table 3). Although the absolute risk is low, the odd's ratio's show that the odd's of receiving complete BCT were higher in both hospital categories in the Northern Netherlands.

| Variable               | North high IP N(%) | North low IP N(%) | Rotterdam high IP N(%) | Rotterdam low IP N(%) | Controls N(%) |
|------------------------|--------------------|-------------------|------------------------|-----------------------|---------------|
| Mean age at diagnosis  |                    |                   |                        |                       |               |
| 6 hospitals            | 61.16              | 61.48             | 61.33                  | 61.40                 | 59.80         |
| 7 hospitals            |                    |                   |                        |                       |               |
| SD 14.16               | SD 14.20           | SD 14.34          | SD 14.39               | SD 13.67              |               |
| Period of diagnosis    |                    |                   |                        |                       |               |
| 1990-1995              | 3260 (23.21)       | 2095 (19.42)      | 2310 (23.16)           | 2249 (23.28)          | 4454 (23.38)  |
| 1996-2001              | 4079 (29.05)       | 3085 (28.60)      | 2717 (27.24)           | 2635 (27.28)          | 5131 (26.93)  |
| 2002-2007              | 4426 (31.52)       | 3558 (32.98)      | 3082 (30.90)           | 3044 (31.51)          | 5995 (31.47)  |
| 2008-2010              | 2278 (16.22)       | 2050 (19.00)      | 1866 (18.71)           | 1732 (17.93)          | 3470 (18.22)  |
| Stage                  |                    |                   |                        |                       |               |
| IS                     | 1097 (7.81)        | 776 (7.19)        | 794 (7.96)             | 775 (8.02)            | 1577 (8.28)   |
| 1                      | 4758 (33.88)       | 3660 (33.93)      | 3323 (33.31)           | 3249 (33.63)          | 6595 (34.62)  |
| 2                      | 5881 (41.88)       | 4575 (42.41)      | 4243 (42.54)           | 4097 (42.41)          | 7898 (41.46)  |
| 3                      | 1480 (10.54)       | 1123 (10.41)      | 1018 (10.21)           | 959 (9.93)            | 1835 (9.63)   |
| 4                      | 718 (5.11)         | 547 (5.07)        | 513 (5.14)             | 487 (5.04)            | 877 (4.60)    |
| X                      | 109 (0.78)         | 107 (0.99)        | 84 (0.84)              | 93 (0.96)             | 268 (1.41)    |
| Average annual volume of hospital of diagnosis | 924 (6.58) | 647 (6.00) | 0 (0.00) | 0 (0.00) | 953 (5.00) |
| <50                    | 4226 (30.09)       | 10141 (94.00)     | 9975 (100)             | 9660 (100)            | 16,579 (87.03) |
| 100 or more            | 8893 (63.33)       | 0 (0.00)          | 0 (0.00)               | 0 (0.00)              | 1518 (7.97)   |

Characteristics of breast cancer patients according to the hospital category, 1990–2010, data are no (%), N = 63,516. IP = Implementation Proportion of recommendations given in the programme.
Introduction of the SNB
Since 2003 guidelines recommend the SNB to be performed in T1-2/N0 breast cancer. Unfortunately, the SNB was not registered consistently in the NCR in some regions of the country. When an ALND was performed after SNB then only the ALND has been registered in these regions. This might give an underestimation of the group that had a BCT with SNB followed by ALND. In our study, this only concerns the control group. We excluded all patients from the control group that were diagnosed in hospitals with this deviating registration policy (N = 1950). The control group remained the largest group. Patients in the control region were more likely to receive a sentinel node biopsy compared to both intervention regions. The differences were most prominent between 1996–2001 (Table 3).

Radiotherapy after BCS for DCIS
The total numbers of patients are low in the early periods. After the introduction of a nationwide screening programme the incidence of DCIS has gradually risen because of the increasing quality of diagnostics. In the latest time period the percentage of radiotherapy was over 79% in all hospital categories. No significant differences

Table 3 Chances of receiving multidisciplinary treatment

| Treatment                                                             | Hospital category | % of patients treated according to guidelines | OR   | 95% CI          |
|----------------------------------------------------------------------|------------------|---------------------------------------------|------|----------------|
| Complete breast conserving treatment. N = 22453                      | Controls         | 95.6  92.3  93.4  95.8 | 1.00 | Reference      |
| Inclusion criteria: Stage I-IIA                                      | North High IP    | 97.8  97.1  97.8  98.3 | 2.68*| 2.08-3.45      |
| Exclusion criterium: Breast amputation after BCS                     | North Low IP     | 95.4  96.3  96.7  97.1 | 1.77*| 1.43-2.17      |
| Rotteram High IP                                                     | 93.0  88.9  91.9  96.7 | 0.77*| 0.64-0.92      |
| Rotterdam Low IP                                                     | 94.6  89.6  91.7  95.0 | 0.72*| 0.60-0.85      |
| Introduction of the SNB. N = 25612                                   | Controls         | 0    33.9  93.6  98.3 | 1.00 | Reference      |
| Inclusion criteria: cT1-2, cN0, cM0, BCS                             | North high IP    | 0    16.2  93.9  98.8 | 0.68*| 0.55-0.84      |
| North low IP                                                         | 0    20.9  93.2  98.2 | 0.59*| 0.50-0.70      |
| Rotteram high IP                                                     | 0    19.1  89.0  98.8 | 0.46*| 0.38-0.55      |
| Rotterdam low IP                                                     | 0    14.8  92.1  96.9 | 0.48*| 0.40-0.57      |
| Radiotherapy after BCS for DCIS. N = 2414                             | Controls         | 16.1  31.7  76.8  85.2 | 1.00 | Reference      |
| Inclusion criteria: DCIS, BCS                                       | North high IP    | 50.0  49.0  74.8  84.9 | 1.24 | 0.88-1.74      |
| North low IP                                                         | 57.1  43.7  72.5  81.7 | 1.13 | 0.84-1.52      |
| Rotteram high IP                                                     | 33.3  48.9  72.0  79.8 | 1.08 | 0.79-1.49      |
| Rotterdam low IP                                                     | 27.6  50.4  74.1  83.3 | 1.27 | 0.93-1.73      |
| Adjuvant radiotherapy locally advanced breast cancer N = 1511        | Controls         | 64.6  67.3  64.6  69.1 | 1.00 | Reference      |
| Inclusion criteria: cT3,anyN,M0 and any T,N2-3,M0 + amputation       | North high IP    | 53.5  54.4  53.5  68.3 | 0.75 | 0.51-1.10      |
| North low IP                                                         | 46.2  62.5  46.2  53.2 | 0.56*| 0.39-0.80      |
| Rotteram high IP                                                     | 39.2  34.2  39.2  61.5 | 0.40*| 0.29-0.55      |
| Rotterdam low IP                                                     | 29.7  35.9  29.7  68.6 | 0.36*| 0.25-0.52      |
| Adjuvant chemotherapy early stage breast cancer. N = 9511            | Controls         | 51.3  73.1  85.1  91.9 | 1.00 | Reference      |
| Inclusion criteria: pT1-2 M0/X, surgery age < 60                     | North high IP    | 62.3  69.7  90.4  93.0 | 1.24 | 1.00-1.54      |
| North low IP                                                         | 52.8  70.6  91.4  91.3 | 1.29*| 1.07-1.54      |
| Rotteram high IP                                                     | 60.2  72.3  88.0  95.6 | 1.50*| 1.26-1.81      |
| Rotterdam low IP                                                     | 55.3  67.2  90.1  96.0 | 1.22*| 1.01-1.46      |
| Neo-adjuvant chemotherapy T4/M0 breast cancer. N = 1484              | Controls         | 5.1   27.4  34.5  61.9 | 1.00 | Reference      |
| Inclusion criteria: cT4NeM0, surgery                                 | North high IP    | 11.2  25.0  56.0  65.3 | 1.23 | 0.73-2.09      |
| North low IP                                                         | 4.8   22.8  57.8  44.0 | 1.57*| 1.00-2.47      |
| Rotteram high IP                                                     | 6.7   28.0  55.0  51.9 | 2.67*| 1.74-4.07      |
| Rotterdam low IP                                                     | 5.3   29.2  54.8  61.5 | 2.02*| 1.32-3.08      |

Odds ratio’s for receiving multidisciplinary therapy per hospital category. Adjusted for age, year of incidence, annual volume of diagnoses per hospital, stage (if necessary). 1990–2010 *P < 0.05. IP = implementation proportion of recommendations given in the programme.
were seen between the odd's for receiving radiotherapy in the different hospital categories (Table 3).

**Adjuvant radiotherapy for locally advanced breast cancer**
Official guideline introduction of adjuvant radiotherapy for locally advanced breast cancer (T3/M0 or any T,N2-3/M0), was in 2002 and a large variation existed before and afterwards (Table 3). The control and Northern region hospitals with the highest IP show the best implementation of this recommendation of the guideline while especially before 2008 patients in the other regions were less likely to receive adjuvant radiotherapy.

**Adjuvant chemotherapy for early stage breast cancer**
Patients diagnosed in hospitals in the Rotterdam region and Northern Netherlands with a low IP received adjuvant chemotherapy more often for early stage breast cancer than patients in the control hospitals (Table 3). Guideline follow-up in the later time-periods is high and differences between the different hospital categories are small.

**Neo adjuvant chemotherapy for T4/M0 breast cancer**
Neo-adjuvant chemotherapy for T4/M0 cancer is administered to approximately half of the patients in the latest time period (Table 3). Because this concerns high stage disease, patient preferences may play an important role in this variation. Both hospital categories in the Rotterdam region as well as the Northern low IP hospitals perform better compared to the control group, with the highest chance of receiving neo adjuvant chemotherapy in the Rotterdam hospitals with high IP (OR 2.67, 95% CI 1.74-4.07, Table 3).

**Discussion**
The results of our study show variation in the multidisciplinary treatment of breast cancer patients in the Netherlands. No relationship was evident between variation in multidisciplinary treatment for breast cancer patients and participating in the external peer review programme for multidisciplinary cancer care. In the Northern Netherlands, only the completeness of breast conserving therapy (stadium I-IIIA) was better in patients diagnosed in hospitals with a higher IP compared to the control group. Patients from hospitals with the lowest IP more often received adjuvant chemotherapy for early stage breast cancer, neo-adjuvant chemotherapy for T4 breast cancer and complete breast conserving therapy. In the Rotterdam region, patients diagnosed in hospitals with the highest IP were more likely to receive neo-adjuvant chemotherapy for T4 breast cancer and adjuvant chemotherapy for early stage breast cancer. The latter results also account for patients from hospitals with a low IP from the Rotterdam region when compared to the control group. Differences between the regions imply that there are regional factors that are responsible for the variation.

Before 2002, there was regional variation in guidelines. Table 3 shows that variation decreased in the periods from 2002–2007 and 2008–2010 but no early adopter effect was seen in patients from hospitals with a higher IP. A previous study by van Steenbergen et al. on early stage breast cancer also showed decreased variation after the introduction of national evidence-based guidelines in 2002 but variation still persisted. Differences could be partly explained by hospital characteristics but also by loco-regional practices. Adjuvant systemic therapy was found to be mainly influenced by patient and tumour characteristics [17]. Another study on early stage breast cancer confirms the important role of the national evidence-based guidelines and identified age as the most important factor in the decision whether a patient receives systemic therapy. They also found the presence of early and late-adopters amongst hospitals but could not determine the role of physicians or hospital characteristics [18]. The programmes in the Northern Netherlands and Rotterdam region were similar in origin. During the second cycle in the Rotterdam region, the focus shifted from the evaluation of basic organisational topics to implementing plan-do-check-act cycles and the measurement of quality within hospitals. This shift also occurred in the Northern region but the basic organisational topics remained part of the programme.

The main weakness of our study was that we had to use a black box approach concerning the supposed mechanism through which external peer review on hospital level exerts its influence on tumour service levels. Moreover we did not have the possibility of correcting possible confounding factors such as comorbidity and patient preference. The gradual spread of the programme over the country gave us the possibility to use a control group, creating a quasi-experimental situation. Hospitals in the control group are likely to have introduced changes in their organisation too, but we are not aware of similar programmes that have been used. Hospitals from the high IP and low IP groups may have had different starting points concerning organisational quality, unfortunately we did not have a baseline measurement of organisational quality. Therefore, we can not answer the question if hospitals that already had a good multidisciplinary organisation also performed well on implementing the recommendations from the programme.

Research in this field is challenging. Besides the ‘quasi-experimental’ situation (due to the gradual introduction of the programme) our study had multiple characteristics that helped us to evaluate the impact of external peer review. In the intervention regions all hospitals participated in the programme (even though they did not all give permission to use their data in this study). Because of this, there was no programme participation bias. We did not rank the importance of
recommendations to assess the programme impact instead of the impact of single recommendations. We were able to analyse results on a ‘patient level’ because of the reliable and complete data, including information on treatment, over a long period of time provided by the Netherlands Cancer Registry.

Conclusion
Our study showed regional differences and did not reveal benefits in the multidisciplinary treatment of breast cancer patients being treated in hospitals participating in the programme nor did the extent in which the hospitals implemented the recommendations seem to matter. Organisation focused quality improvement programmes are generally not designed to directly improve clinical care and in methodological terms this can still be considered as a “black box intervention”. Improving the organisation of care seems a justified goal, but it may be questioned whether the effort put into it is justified if no clinical benefits can be shown. If the objective is that external quality assessment programmes should have a measurable effect on clinical outcomes, the programmes should change their approach. A better focus on the actual delivery of clinical care and incorporating reliable outcome data (from cancer registries) can bridge the gap between quality improvement and patient outcomes. Variation in treatment, as shown in our study can be used as a starting point for quality improvement programmes for hospitals to work on their organisation and delivery of care.

Additional file

Additional file 1: The external peer review programme for multidisciplinary cancer care in the Netherlands.

Abbreviations
NCR: Netherlands Cancer Registry; IP: Implementation Proportion; BCT: Breast Conservation Therapy/Treatment; BCS: Breast Conservation Surgery; ALND: Axillary Lymph Node Dissection; SNB: Sentinel Node Biopsy; DCIS: Ductal Carcinoma In Situ.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MK designed the study, performed statistical analysis and wrote and revised the paper. BVD performed statistical analysis, critically revised the article for important intellectual content; and read and approved the final draft. RO contributed to the initial study idea, critically revised the article for important intellectual content and read and approved the final draft. WH contributed to the initial study idea, study design, critically revised the article for important intellectual content; and read and approved the final draft. SS contributed to the initial study idea, study design, critically revised the article for important intellectual content; and read and approved the final draft. All authors read and approved the final manuscript.

Acknowledgments
We would like to thank G. Sonke MD PhD, oncologist in the Netherlands Cancer Institute (NKI-AVL) for his valuable research advice and critical reading of the manuscript. Moreover we would like to thank all participating hospitals for their participation in this project. We would like to thank all physicians, nurses and management representatives from both intervention regions that cooperated in interviews for the valuable discussions on the perceived (clinical) impact of the programme (results will be published separately). The authors thank the registration teams of the Comprehensive Cancer Centre Netherlands and Comprehensive Cancer Centre South for the collection of data for the Netherlands Cancer Registry and the scientific staff of the Comprehensive Cancer Centre Netherlands. No funding was acquired for this study. No writing assistance was obtained.

Author details
1Comprehensive Cancer Centre the Netherlands, Department of Research, Postbus 19079, 3501 DB Utrecht, The Netherlands. 2University of Twente, School for Management and Governance, Department Health Technology and Services Research, Enschede, The Netherlands. 3Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands. 4The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Received: 13 September 2013 Accepted: 28 July 2014
Published: 16 August 2014

References
1. Netherlands Cancer Registry: Dutch Cancer Figures. http://www.cijfersoverkanker.nl/?language=en.
2. Petro R, Boreham J, Clarke M, Davies C, Beal V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 2000, 355(9217):1822.
3. Thomson CS, Brewster DH, Dewar JA, Twelvees CJ, Scottish Cancer Therapy Network: Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. Eur J Cancer 2004, 40(5):743–753.
4. Kessons EM, Allardice GM, George WD, Burns HJ, Morrison DS: Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ 2012, 344:e2718.
5. Selby P, Gillis C, Haward R: Benefits from specialised cancer care. Lancet 1996, 348(9023):313–318.
6. Kingsmore D, Stenwogereere A, Hole D, Gillis C: Specialisation and breast cancer survival in the screening era. Br J Cancer 2003, 88(11):1708–1712.
7. Roberts CM, Stone RA, Buckingham RJ, Pursey NA, Lowe D, Potter JM: A randomised trial of peer review: the UK national chronic obstructive pulmonary disease resources and outcomes project: three-year evaluation. J Eval Clin Pract 2012, 18(3):599–605.
8. Roberts CM, Stone RA, Buckingham RJ, Pursey NA, Harrison BD, Lowe D, Potter JM: A randomised trial of peer review: the UK national chronic obstructive pulmonary disease resources and outcomes project. Clin Med 2010, 10(3):223–227.
9. Greenfield D, Braithwaite J: Health sector accreditation research: a systematic review. Int J Qual Health Care 2008, 20(3):172–183.
10. Hinchcliff R, Greenfield D, Moldovan M, Westbrook J, Pawsley M, Munford V, Braithwaite J: Narrative synthesis of health service accreditation literature. BMJ Qual Saf 2012, 21(11):979–991.
11. Shaw C: External assessment of health care. BMJ 2001, 322(7290):851–854.
12. Greenfield D, Braithwaite J: Developing the evidence base for accreditation of healthcare organisations: a call for transparency and innovation. Qual Saf Health Care 2009, 18(3):162–163.
13. Kilsdonk MJ, van Dijk BA, Otter R, Siesling S, van Harten WH: The impact of organisational external peer review on colorectal cancer treatment and survival in the Netherlands. Br J Cancer 2014, 110(4):859–858 th.
14. Schouten LJ, Jager JJ, van den Brandt PA: Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. Br J Cancer 1993, 68(5):974–977.
15. Schouten LJ, Hoppener P, van den Brandt PA, Knottnenus JA, Jager JJ: Completeness of cancer registration in Limburg. Netherlands Int J Epidemiol 1993, 22(3):369–376.
16. Dutch Institute for Clinical Auditing (DICA). NABON Breast Cancer Audit. http://nbca.clinicalaudit.nl.
17. van Steenbergen LN, van de Poll-Franse LV, Wouters MW, Jansen-Landheer ML, Coebergh JW, Struikmans H, Tjan-Heijnen VC, van de Velde CJ: Variation in management of early breast cancer in the Netherlands, 2003–2006. *Eur J Surg Oncol* 2010, 36(Suppl 1):S36–S43.
18. Sukel MP, van de Poll-Franse LV, Nieuwenhuizen GA, Vreugdenhil G, Herings RM, Coebergh JW, Voogd AC: Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990–2006 in the southeastern Netherlands. *Eur J Cancer* 2008, 44(13):1846–1854.

doi:10.1186/1471-2407-14-596

Cite this article as: Kilsdonk et al: Regional variation in breast cancer treatment in the Netherlands and the role of external peer review: a cohort study comprising 63,516 women. *BMC Cancer* 2014 14:596.